Intellipharmaceutics out-licenses antidepressant in U.S. to Tris Pharma

Intellipharmaceutics (OTC:IPCI +0.4%) inks an agreement with Tris Pharma granting the latter exclusive distribution rights to five strengths of antidepressant Quetiapine ER in the U.S. Financial terms are not disclosed.

The branded product is marketed as Seroquel XR by AstraZeneca.

https://seekingalpha.com/news/3492363-intellipharmaceutics-licenses-antidepressant-u-s-tris-pharma